Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Summary of Bispecific Antibodies for Follicular Lymphoma

UChicago Medicine

D. Russler-Germain

Overview of CNS Cancers

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

V. Venur

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Follicular Lymphoma Management: What Is the New Order?

SOHO 2023 Eleventh Annual Meeting

B. Kahl

FDA Approval of Zanubrutinib in R/R FL: What You Need to Know

Christopher Flowers

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Summary of Recent Advances in Follicular Lymphoma

Louisville Hematology Highlights

S. Gaballa

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

FDA Approval of Epcoritamab in R/R FL: What You Need to Know

Yasmin Karimi

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Tazemetostat in R/R FL: Impact of EZH2 Mutational Status on PFS

Bruce D. Cheson

Treatment Landscape in Follicular Lymphoma

Mitchell Smith

Tazemetostat in Older Frail Adults With Follicular Lymphoma

Erin Mulvey

Practice-Changing Abstracts in NHL and HL From ASH 2023

UChicago Medicine

S. Smith